What does Connect Biopharma Holdings Limited do?
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).…
What is Connect Biopharma Holdings Limited's P/E and P/B ratio?
Connect Biopharma Holdings Limited has a P/E ratio of -0.6 and a P/B ratio of 1.79.
What is Connect Biopharma Holdings Limited's debt-to-equity ratio?
Connect Biopharma Holdings Limited has a debt-to-equity ratio of 0.02.
How much does Connect Biopharma Holdings Limited owe compared with what it owns?
Connect Biopharma Holdings Limited owes $0.38 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Connect Biopharma Holdings Limited's Positivity rank?
Connect Biopharma Holdings Limited is ranked #1,048 of 6,774 companies globally and #202 of 4,000 in United States on PositoAI, with a Positivity Score of 23,300.
Does Connect Biopharma Holdings Limited have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Connect Biopharma Holdings Limited.
Where can I read the latest news about Connect Biopharma Holdings Limited?
Recent headlines about Connect Biopharma Holdings Limited from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Connect Biopharma Holdings Limited have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Connect Biopharma Holdings Limited's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.